Arbor Biotechnologies

Arbor Biotechnologies, a next-generation gene editing company based in Cambridge, MA, is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions from the ultra-rare to the most common genetic diseases. The companys unique suite of optimized gene editors, which is capable of approaches ranging from gene... knockout, excisions, reverse transcriptase editing, and large gene insertion, goes beyond the limitations of early editing technologies to unlock access to new gene targets and has fueled a robust pipeline of first-in-class assets focused on diseases of high unmet need. With Arbors lead program, ABO-101 for the treatment of primary hyperoxaluria type 1, in clinical development, the company continues to focus their research and development efforts on genomic diseases of the liver and CNS for which there are no existing functional cures.Read More